The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

Ole Jakob Storebø; Erlend Faltinsen; Morris Zwi; Erik Simonsen; Christian Gluud

doi:10.1002/cpt.1149

The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

Ole Jakob Storebø^*
, Erlend Faltinsen
, Morris Zwi
, Erik Simonsen
, Christian Gluud

^*Corresponding author af dette arbejde

Forskningsafdelingen

Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning

Abstract

Much remains unclear about the benefits and harms of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Between 2012 and 2018, we conducted two Cochrane systematic reviews on methylphenidate for ADHD. This article explores the main findings in relation to evidence-based practice and our current understanding of ADHD.

Originalsprog	Engelsk
Sider (fra-til)	606-609
Antal sider	4
Tidsskrift	Clinical Pharmacology and Therapeutics
Vol/bind	104
Udgave nummer	4
DOI	https://doi.org/10.1002/cpt.1149
Status	Udgivet - okt. 2018

Adgang til dokumentet

10.1002/cpt.1149

Andre filer og links

https://www.scopus.com/pages/publications/85050946131

Citationsformater

@article{f3d74b44eae64571ab64ed096f8cce3f,

title = "The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder",

abstract = "Much remains unclear about the benefits and harms of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Between 2012 and 2018, we conducted two Cochrane systematic reviews on methylphenidate for ADHD. This article explores the main findings in relation to evidence-based practice and our current understanding of ADHD.",

author = "Storeb{\o}, \{Ole Jakob\} and Erlend Faltinsen and Morris Zwi and Erik Simonsen and Christian Gluud",

year = "2018",

month = oct,

doi = "10.1002/cpt.1149",

language = "English",

volume = "104",

pages = "606--609",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

AU - Storebø, Ole Jakob

AU - Faltinsen, Erlend

AU - Zwi, Morris

AU - Simonsen, Erik

AU - Gluud, Christian

PY - 2018/10

Y1 - 2018/10

N2 - Much remains unclear about the benefits and harms of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Between 2012 and 2018, we conducted two Cochrane systematic reviews on methylphenidate for ADHD. This article explores the main findings in relation to evidence-based practice and our current understanding of ADHD.

AB - Much remains unclear about the benefits and harms of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Between 2012 and 2018, we conducted two Cochrane systematic reviews on methylphenidate for ADHD. This article explores the main findings in relation to evidence-based practice and our current understanding of ADHD.

UR - https://www.scopus.com/pages/publications/85050946131

U2 - 10.1002/cpt.1149

DO - 10.1002/cpt.1149

M3 - Comment/debate

C2 - 30006934

AN - SCOPUS:85050946131

SN - 0009-9236

VL - 104

SP - 606

EP - 609

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 4

ER -

The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater